

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

NCT07219407

Status	RECRUITING
Phase	Phase 2
Sponsor	Rapport Therapeutics Inc.
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (7)

- Completion of the associated parent study (RAP-219-FOS-201) treatment period with acceptable tolerability, per Investigator.
- Diagnosis of refractory focal epilepsy
- Stable RNS(c) system settings
- A demonstrated history of compliance with RNS(c) system data interrogation and upload
- Good overall health other than focal epilepsy, per Investigator.

... and 2 more (see full listing online)

Exclusion (3)

- Known of hypersensitivity to RAP-219
- Any clinically unstable or serious medical, neurological (other than epilepsy), psychological, or behavioral problem; laboratory or ECG finding that would increase participant risk or should otherwise exclude the patient from participation, as assessed by Investigator
- Pregnancy, lactation, or individuals of reproductive potential who do not agree to simultaneously use two effective birth-control methods

Locations (7 total)

Consultants in Epilepsy and Neurology, PLLC, Boise, Idaho, United States
Mayo Clinic, Rochester, Minnesota, United States
NYU Langone Comprehensive Epilepsy Center, New York, New York, United States
... and 4 more locations